Autopsy report · NCT02258854
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
Cause of deathNo reason given
Life of this trial
- Registered 7 months after it had already started.
- Ran for about 3 years 9 months before it stopped.
- 69 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- XOMA (US) LLC
- Sponsor type
- Industry
- Conditions
- Uveitis
- Interventions
- Dose 2 gevokizumab
- Participants
- 69
- Sites
- 33
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.